The ability of Mylan to raise EpiPen’s list price by nearly 550% over the past eight years underscores the pricing power drug companies enjoy for iconic brands facing little competition.
Hong Kong’s legal action against a short seller’s research will have a chilling effect for independent analysis, left and right.
As investors debate whether markets are calm, the hope is Janet Yellen’s Jackson Hole speech provides more clarity than confusion.
The European corporate bond market is heading into ever more extraordinary territory.
The cloud company’s valuation curbs enthusiasm, but performance stays strong.
Political outrage over EpiPen price increases won’t help lower health-care costs for Americans.
After years battling depressed prices and cost-cutting, South African gold miners are regaining their shine, with the country’s top four gold producers announcing soaring profits and dividends.
Merck KGaA is expanding its specialty chemicals and lab equipment operations to keep its revenue and profit growing despite recent drug-development stumbles.
A dozen big-name universities, including Duke, Cornell and Yale, have been hit with lawsuits alleging their retirement plans are too confusing and costly.
Upgrade Your Home Heating and Air-Conditioning System to Ductless! Sign up to recieve a FREE in home estimate and $100.00 off Coupon!*
0% financing and up to $1350 in rebates are available
Why Go Ductless?